Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2026-05-04 16:22:25 ET · period of report 2026-04-30 · accession 0001470831-26-000410 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-05-04 16:22 | 2026-04-30 | BBIO | Apuli Maricel | CAO | S - Sale | $71.58 | -2,000 | 134.1K | -1% | -$143.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-30 | S | D | 2,000 | $71.58 | 134,115 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025. |